Core Viewpoint - The non-liquor sector experienced a decline of 0.48% on September 30, with Kuaijishan leading the drop, while the Shanghai Composite Index rose by 0.52% to close at 3882.78 [1][2]. Market Performance - The Shanghai Composite Index closed at 3882.78, up 0.52% - The Shenzhen Component Index closed at 13526.51, up 0.35% - The non-liquor sector saw a decline of 0.48% [1]. Stock Performance - Kuaijishan (601579) closed at 20.52, down 1.91% with a trading volume of 66,700 shares and a turnover of 138 million yuan - Other notable stocks include: - ST Xifa (000752) closed at 11.12, down 2.02% - Pearl River Beer (002461) closed at 10.01, down 0.89% - Zhangyu A (000869) closed at 21.67, down 0.60% [2]. Capital Flow - The non-liquor sector saw a net outflow of 98.50 million yuan from main funds, while retail funds had a net inflow of 65.63 million yuan [2][3]. - The main funds' net inflow for Pearl River Beer was 4.59 million yuan, while Zhangyu A experienced a net inflow of 4.31 million yuan [3].

Core Viewpoint - DBS maintains a "Buy" rating for Budweiser APAC (01876) due to low valuation and attractive dividend yield, while lowering the target price from HKD 9.6 to HKD 9.4 [1] Financial Forecasts - DBS has reduced Budweiser APAC's earnings forecast for FY2025 by 11% due to weak performance in the Chinese market [1] - Earnings forecasts for FY2026 and FY2027 have been lowered by 5% each [1] Market Performance - The company is expected to face pressure on sales volume and average selling price in the Chinese market for Q3 this year [1] - Streamlined channel inventory is anticipated to pave the way for potential sales rebound in Q4 [1] - Budweiser APAC's performance in South Korea has been strong, supported by favorable brand and channel mix as well as price increase measures, leading to a significant rise in average selling price [1]

Group 1 - The core point of the article is the appointment of Cao Dong as the new CEO of JD Health, following the resignation of Jin Enlin for family reasons [1] - Cao Dong has been with JD since January 2012 and has held various leadership roles within the financial system of JD Group, including CFO of JD Health from April 2019 to May 2023 [1] - The board of directors of JD Health will now include Cao Dong as the executive director, along with other members such as Liu Qiangdong and independent directors [1] Group 2 - JD Health reported a revenue of 35.29 billion RMB for the first half of 2025, representing a year-on-year increase of 24.5%, with a net profit of 3.57 billion RMB, up 35% [2] - For the full year of 2024, JD Health's revenue was 59.93 billion RMB, showing a year-on-year growth of 11.55%, while the net profit attributable to shareholders was 4.16 billion RMB, increasing by 94.31% [2] - As of the report date, JD Health's stock price rose by 1.63% to 65.55 HKD, with a total market capitalization of 209.86 billion HKD [2]

Core Viewpoint - DBS maintains a "Buy" rating on Budweiser APAC (01876) due to low valuation and attractive dividend yield, adjusting the target price from HKD 9.6 to HKD 9.4 [1] Financial Forecasts - The earnings forecast for Budweiser APAC for FY2025 has been reduced by 11% due to weak performance in the Chinese market [1] - Earnings forecasts for FY2026 and FY2027 have each been lowered by 5% [1] Market Performance - Despite anticipated pressure on sales and average selling prices in the Chinese market for Q3, streamlined channel inventory is expected to pave the way for potential sales rebound in Q4 [1] - Budweiser APAC's performance in South Korea has been strong, supported by favorable brand and channel mix as well as price increase measures, leading to a significant rise in average selling prices [1]

Core Viewpoint - Despite anticipated sales and average price pressures in the Chinese market for Budweiser APAC in Q3, streamlined channel inventory may pave the way for potential sales rebound in Q4 [1] Group 1: Market Performance - Budweiser APAC's performance in South Korea is strong, driven by favorable brand and channel mix along with price increase measures, significantly supporting average price uplift [1] Group 2: Financial Forecasts - DBS has lowered its earnings forecast for Budweiser APAC by 11% for FY2025, and by 5% for FY2026 and FY2027 [1] Group 3: Investment Rating - Despite the lowered earnings forecasts, the company maintains a "Buy" rating due to low valuation and attractive dividend yield, with the target price adjusted from HKD 9.6 to HKD 9.4 [1]

Core Viewpoint - Morgan Stanley predicts that Budweiser APAC's Q3 natural revenue and EBITDA will decline by 7% and 9% year-on-year, with a worsening trend compared to Q2's declines of 3.9% and 4.5% [1] Group 1: Market Performance - The Chinese market continues to drag down performance, with moderate demand affected by current anti-extravagance policies and intense promotions from delivery platforms [1] - The South Korean market also shows a slowdown in Q3 due to weakened consumer sentiment, although price increases in November 2024 and April 2025 are expected to provide support [1] Group 2: Future Projections - For 2025, Budweiser APAC's sales and EBITDA are forecasted to decline by 4.7% and 5.7% year-on-year, with a compound annual growth rate of 4.5% and 6.5% from 2025 to 2027, excluding exchange rate factors [1] - The company is expected to increase its dividend payout ratio to 125% to maintain a total dividend of $750 million in 2025, implying a dividend yield of 5.5%, which provides downside support for the stock price [1] Group 3: Rating and Target Price - Morgan Stanley maintains a "Neutral" rating on Budweiser APAC, lowering the target price from HKD 9 to HKD 8.5 [1]

Core Viewpoint - Morgan Stanley has downgraded Budweiser APAC's target price by 5.6% from HKD 9 to HKD 8.5, maintaining a "Neutral" rating [1] Financial Projections - The company’s EBITDA forecast has been reduced by 5-7%, with expected sales and EBITDA for 2025 projected to decline by 4.7% and 5.7% year-on-year, respectively [1] - For the period of 2025-2027, a compound annual growth rate (CAGR) of 4.5% for sales and 6.5% for EBITDA is anticipated, excluding foreign exchange effects [1] Dividend Expectations - The dividend payout ratio is expected to increase to 125% to maintain a total dividend of USD 750 million for 2025, which is consistent with 2024, resulting in an attractive dividend yield of 5.5 that may support the stock price [1] Market Performance Insights - In Q3 2025, organic revenue and EBITDA are expected to decline by 7% and 9% year-on-year, respectively, with a more significant drop compared to Q2 [1] - The Chinese market continues to be a drag due to anti-extravagance policies and promotional activities that have accelerated the overall market demand slump [1] - Despite a low base, EBITDA growth in the Chinese market is expected to turn positive in Q4 2025 [1] - The South Korean market is also experiencing a slowdown in Q3 2025 due to weak consumer sentiment, although price increases are providing some positive momentum that may continue into Q4 2025 [1]

小摩下调对该公司EBITDA预测5-7%后，预计百威亚太2025年的销售额/EBITDA将同比下降 4.7%/5.7%，2025-2027年期间实现4.5%/6.5%的复合年增长率（扣除外汇基本）。小摩预计其派息比率 将提高至125%，以维持2025年7.5亿美元的总股息（与2024年持平），这意味着5.5%的股息收益率将具 有吸引力，为股价下行提供支撑。 智通财经APP获悉，摩根大通发布研报称，下调百威亚太(01876)目标价5.6%，从9港元下调至8.5港元， 维持"中性"评级。 小摩预计，百威亚太2025年第三季度有机收入/EBITDA同比下降7%/9%， 跌幅高于第二季度。中国市 场仍然是个拖累，反奢靡政策以及外卖促销活动加速整体市场需求的低迷。鉴于基数较低，小摩预计中 国市场EBITDA增长将在2025年第四季转正。由于消费情绪疲软，韩国市场2025年第三季也出现放缓。 然而，价格上升带来的利好对增长有帮助，这种势头或持续到2025年第四季。 ...

Summary of Key Points Core Viewpoint - The report highlights the top short-selling stocks in the market, indicating significant investor sentiment and potential volatility in these companies' stock prices [1][2]. Group 1: Top Short-Selling Ratios - China Resources Beer (80291) and Anta Sports (82020) both have a short-selling ratio of 100.00%, indicating complete short interest [1][2]. - Lenovo Group (80992) has a short-selling ratio of 72.39%, suggesting a notable level of bearish sentiment among investors [1][2]. Group 2: Top Short-Selling Amounts - Alibaba (09988) leads with a short-selling amount of 5.5 billion, followed by Xiaomi (01810) at 3.305 billion and Tencent Holdings (00700) at 2.414 billion [2]. - The significant short-selling amounts for these companies may reflect concerns about their future performance or market conditions [2]. Group 3: Top Short-Selling Deviations - COSCO Shipping International (00517) has the highest deviation at 36.57%, indicating a substantial difference between its current short-selling ratio and its average over the past 30 days [1][2]. - China Resources Beer (80291) follows with a deviation of 32.83%, suggesting heightened short-selling activity compared to its historical average [1][2].

Core Viewpoint - The white liquor market is experiencing a slow recovery in demand as the Mid-Autumn Festival approaches, with expectations of a year-on-year decline in sales during the National Day and Mid-Autumn holiday period by approximately 15% to 20% [1] Industry Summary - The current focus in the white liquor market is on inventory adjustment through bottle opening and sales [1] - The consumption of white liquor in banquet settings and the mass price segment is expected to perform relatively better [1] - The bottom of the industry fundamentals is anticipated to appear in the third quarter of 2025, with the third quarter of this year expected to be the most challenging period for sales, prices, and market confidence [1] - The second half of this year is projected to be the most pressured period for the financial performance of white liquor listed companies, but a gradual recovery trend is expected thereafter, presenting bottom-fishing opportunities in the industry [1] Beer Industry Summary - The beer sector is expected to maintain stable pre-holiday stocking rhythms due to a lower base in the second half of the year [1] - However, increased competition and the impact of alcohol restrictions are anticipated to exert pressure on the financial reports for the third quarter [1]